ADC Therapeutics SA (ADCT) posted a Q4 2025 adjusted loss of $0.04 per share, wider than the -$0.27 expected loss (8.1% wider). The company generated $22.3M in revenue for the quarter.
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, which received accelerated approval from the U.S.
The Swiss biotech company continues to commercialize its lead asset in the competitive oncology therapeutics market.
A detailed analysis of ADC Therapeutics SA’s quarter follows shortly on AlphaStreet.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.
The post ADC Therapeutics SA (ADCT) Reports Wider Loss Q4 EPS Estimates by 85.1% first appeared on Alphastreet.
